Latest mitoxantrone Stories
According to Ironclad Integrity Ltd MS natural treatments have become all the rage lately as these promise effective results, no side-effects and lower health care bills.
Cabazitaxel (trade name: Jevtana®) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel.
TARRYTOWN, N.Y., July 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
THOUSAND OAKS, Calif., June 27, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S.
NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ -- Recent findings published in the scientific journal Leukemia Research (http://www.sciencedirect.com/science/article/pii/S0145212611002505), showed that when combined with standard anti-leukemia agents, the biological activity of Leukothera(TM), a drug candidate under development by Actinobac Biomed, Inc., showed synergistic anti-leukemia effects.
THOUSAND OAKS, Calif., May 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced primary results of a pivotal Phase 3 trial ('147) demonstrating that XGEVA(TM) (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.
Scientists in Germany have developed a way of smuggling an anti-cancer drug past the protective blood-brain barrier and into brain tumours and metastases using a nanocarrier â€“ a tiny capsule specially designed to pass through cell membranes and deliver its anti-cancer drug to the cancer cell.
BRIDGEWATER, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S.
PARIS, June 17 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S.
SILVER SPRING, Md., June 17 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Jevtana (cabazitaxel), a chemotherapy drug used in combination with the steroid prednisone to treat men with prostate cancer.
- An armed gangster.